Latest News & Features
Americas
A coalition of attorneys general have taken 26 drugmakers, including Pfizer, Sandoz and Mylan, to court over the alleged price-fixing of topical generic drugs. 11 June 2020
Biotechnology
For a start-up looking to build a patent portfolio, where should you start—‘home-grown’ patents, or licensing others’ IP? 11 June 2020
Americas
As opportunistic price-gougers look to capitalise on the COVID-19 pandemic, brands such as 3M have turned to trademark law to try and stop them. Brian Michalek and Erin Westbrook of Saul Ewing Arnstein & Lehr report. 11 June 2020
Americas
Concerns that IP is hindering the development of tools to fight the COVID-19 are unfounded, and now is the time that we need IP the most, according to big pharma representatives. 9 June 2020
Big Pharma
Monster Energy has failed to block a UK trademark filed by German pharmaceutical company Merck KGaA. 9 June 2020
Americas
The US Court of Appeals for the Federal Circuit has said it cannot award attorneys’ fees for proceedings before the US Patent Trial and Appeal Board. 5 June 2020
Big Pharma
The COVID-19 pandemic has seen the fundamental principles of the IP system called into question. How can we go on as before? 5 June 2020
Big Pharma
The advocate general has recommended that the Court of Justice of the European Union uphold an almost €94 million fine imposed on Lundbeck for its pay-for-delay scheme. 5 June 2020
Asia
IP firm Rouse will collaborate with life sciences service provider Codex to support companies looking to enter the Chinese market. 4 June 2020
Big Pharma
In a victory for Mylan, the English High Court has rejected Israel-based pharmaceutical company Neurim’s attempt to delay a generic version of its insomnia medication. 4 June 2020